Overview

• Cancer therapy developer's Q4 revenue rose yr/yr, driven by XPOVIO demand

• Net product revenue for Q4 increased compared to 2024

• Company provides 2026 revenue guidance of $130 mln to $150 mln

Outlook

• Karyopharm expects 2026 total revenue between $130 mln and $150 mln

• Company anticipates top-line data from Phase 3 SENTRY trial in March 2026

• Karyopharm projects U.S. XPOVIO net product revenue of $115 mln to $130 mln for 2026

Result Drivers

• XPOVIO DEMAND - Consistent demand for XPOVIO in multiple myeloma market, with community setting driving 60% of revenue

• GLOBAL ACCESS - Expanded global patient access for selinexor with approvals in over 50 countries, including Spain and China

• CLINICAL TRIALS - Key upcoming data from Phase 3 trials in myelofibrosis and endometrial cancer expected in 2026

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 103.5% above its February 11 closing price of $7.37

Press Release: ID:nPnFXdqga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)